单细胞图谱解析用于开发霍奇金淋巴瘤的嵌合抗原受体T细胞
本研究通过整合肿瘤微环境的单细胞解析和基于单细胞的脱靶抗原预测,在经典霍奇金淋巴瘤(cHL)中确定CD86为有前景的治疗靶点。CD86在霍奇金和Reed-Sternberg癌细胞及cHL特异性肿瘤相关巨噬细胞上高表达,CD86-CTLA-4是关键抑制通路并驱动T细胞耗竭。靶向CD86的细胞疗法在体外和体内有非凡疗效,在免疫健全小鼠模型中安全且不损害脓毒症模型的细菌宿主防御。
要点
- CD86在cHL的霍奇金和Reed-Sternberg癌细胞及cHL特异性肿瘤相关巨噬细胞上高表达。
- CD86-CTLA-4是cHL的关键抑制通路,驱动T细胞耗竭。
- 靶向CD86的细胞疗法在体外和体内有非凡疗效,在免疫健全小鼠模型中安全。
核心结论
- 研究结果证明抗CD86免疫疗法治疗cHL的潜在价值。
研究设计与样本
- 整合单细胞肿瘤微环境解析与基于单细胞的脱靶抗原预测,确定cHL治疗靶点。
主要发现
- CD86在霍奇金和Reed-Sternberg癌细胞及cHL特异性肿瘤相关巨噬细胞上高表达。
- CD86-CTLA-4是关键抑制通路,驱动T细胞耗竭。
- 靶向CD86的细胞疗法在体外和体内有非凡疗效。
- 靶向CD86的细胞疗法在免疫健全小鼠模型中安全,且不损害脓毒症模型的细菌宿主防御。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The success of targeted therapies for hematological malignancies has heralded their potential as both salvage treatment and early treatment lines, reducing the need for high-dose, intensive, and often toxic chemotherapeutic regimens. For young patients with classic Hodgkin lymphoma (cHL), immunotherapies provide the possibility to lessen long-term, treatment-related toxicities. However, suitable therapeutic targets are lacking. By integrating single-cell dissection of the tumor landscape and an in-depth, single-cell-based off-tumor antigen prediction, we identify CD86 as a promising therapeutic target in cHL. CD86 is highly expressed on Hodgkin and Reed-Sternberg cancer cells and cHL-specific tumor-associated macrophages. We reveal CD86-CTLA-4 as a key suppressive pathway in cHL, driving T-cell exhaustion. Cellular therapies targeting CD86 had extraordinary efficacy in vitro and in vivo and were safe in immunocompetent mouse models without compromising bacterial host defense in sepsis models. Our results prove the potential value of anti-CD86 immunotherapies for treating cHL.
引用
- Gottschlich A, Grünmeier R, Hoffmann GV, et al. Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma. Blood. 2025. PMID: 40178843. doi:10.1182/blood.2023022197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。